Home
Resource
Design of antioxidant nanotherapeutics for attenuation of atherogenesis and neuroinflammation
PDF
PDF format is widely accepted and good for printing.
Plug-in required
PDF-1(4.65 MB)
Citation & Export
View Usage Statistics
Staff View

Citation & Export
Hide

Simple citation

Chmielowski, Rebecca Ann. Design of antioxidant nanotherapeutics for attenuation of atherogenesis and neuroinflammation. Retrieved from https://doi.org/doi:10.7282/T32N55GH

Export

Click here for information about Citation Management Tools at Rutgers.

Statistics
Hide

Description

TitleDesign of antioxidant nanotherapeutics for attenuation of atherogenesis and neuroinflammation
NameChmielowski, Rebecca Ann (author); Moghe, Prabhas V (chair); Roth, Charlie (internal member); Uhrich, Kathryn E (internal member); Baum, Jean (internal member); Joseph, Laurie B (outside member); Tugcu, Nihal (outside member); Rutgers University; School of Graduate Studies
Date Created2018
Other Date2018-01 (degree)
SubjectChemical and Biochemical Engineering, Atherosclerosis--Treatment
Extent1 online resource (xiv, 112 p. : ill.)
DescriptionAtherosclerosis and Parkinson’s disease are both characterized by the uncontrolled uptake of modified proteins in chronic inflammatory cells, macrophages/microglia. The initial stages of atherosclerosis are characterized by oxidation of low density lipoprotein and its uptake by macrophages, which can lead to plaque progression in the arterial wall and possibly heart attack or stroke. Formation and increase of misfolded aggregates of proteins such as alpha synuclein (α-synuclein) are a key factor in several neurodegenerative diseases including Parkinson’s disease. Both classes of diseases are exacerbated in macrophages/microglia due to a strong inflammatory component, which has been challenging to treat. The anti-atheroprotective and anti-inflammatory properties of antioxidants create an attractive target for treatment of atherosclerosis and Parkinson’s disease. We propose a library of antioxidant nanoparticles that have the potential to address critical needs for both atherosclerosis and Parkinson’s disease. For atherosclerosis applications, we advanced the delivery and formulation of antioxidants through the development of ferulic acid-based polymer nanoparticles, which are completely biodegradable and can achieve a sustained and tunable release of ferulic acid to limit macrophage foam cell formation. The ferulic acid-based polymer nanoparticles attenuated macrophage lipogenesis and reactive oxygen species generation. The cellular mechanism of the nanoparticle efficacy involved the down regulation of the expression of three scavenger receptors, which are critical for modulation of lipid uptake in macrophages. For neuroinflammatory applications, we developed a dual antioxidant nanoparticle consisting of ferulic acid and tannic acid, which significantly reduced the generation of -synuclein fibrils. This result suggests that the combination of antioxidants and the configuration of nanoparticle vehicles could be important factors for inhibiting -synuclein fibril formation. Overall, antioxidant nanotherapeutics may be promising technologies for inhibition of early stages of both atherosclerosis and Parkinson’s disease.
NotePh.D.
NoteIncludes bibliographical references
Noteby Rebecca Ann Chmielowski
Genretheses, ETD doctoral
Persistent URLhttps://doi.org/doi:10.7282/T32N55GH
Languageeng
CollectionSchool of Graduate Studies Electronic Theses and Dissertations
Organization NameRutgers, The State University of New Jersey
RightsThe author owns the copyright to this work.
Version 8.5.3
Rutgers University Libraries - Copyright ©2023